Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
ACTIVE_NOT_RECRUITING
Status
Conditions
- Hepatocellular Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Biliary Tract Cancers
- Esophageal Squamous Cell Carcinoma
- Triple Negative Breast Cancer
- Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- Head and Neck Squamous-Cell Carcinoma
- Platinum Resistant High Grade Epithelial Ovarian Cancer
Interventions
- DRUG: ABBV-400
- DRUG: Itraconazole (ITZ)
Sponsor
AbbVie